Le point sur la controverse a propos de la rosiglitazone.

Advisory Committees; Clinical Trials as Topic; Diabetes Mellitus, Type 2/drug therapy; Heart Diseases/chemically induced; Humans; Hypoglycemic Agents/adverse effects/therapeutic use; Risk Assessment; Thiazolidinediones/adverse effects/therapeutic use; United States; United States Food and Drug Administration

Abstract :

[en] The present article aims at summarizing the recent controversy about rosiglitazone (Avandia), an insulin sensitizer used as oral antidiabetic agent in the treatment of type 2 diabetes. We will present and briefly discuss 1) the results of the meta-analysis that raised suspicion about a possible excess of coronary complications with rosiglitazone; 2) the more favourable results of the large prospective clinical trial RECORD, but which are currently limited to an interim analysis; and 3) the reassuring data from several large US databases comparing the cardiovascular prognosis of type 2 diabetic patients treated with different antidiabetic drugs. We will conclude, referring to the recent position statement of the Advisory Committee of the Food and Drug Administration, by providing some practical recommendations.

Disciplines :

Endocrinology, metabolism & nutrition

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

De Flines, Jenny ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques

Paquot, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Diabétologie,nutrition, maladies métaboliques

Language :

French

Title :

Le point sur la controverse a propos de la rosiglitazone.

Alternative titles :

[fr] What about the controversy regarding rosiglitazone

Publication date :

2007

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

560-5

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be/index.php?page=resume?num_id=1635

Available on ORBi :

since 16 February 2009

Statistics

Number of views

80 (1 by ULiège)

Number of downloads

185 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

Bibliography

Yki-Järvinen H. - Thiazolidinediones. N Engl J Med, 2004, 351, 1106-1118.
Scheen AJ, Paquot N. - Récepteurs PPAR-γ, nouvelle cible thérapeutique dans les pathologies métaboliques et cardio-vasculaires. Rev Med Liège, 2005, 60, 89-95.
Nathan DM, Buse JB, Davidson MB, et al. - Management of hyperglycemia in type 2 diabetes : a consensus algorithm for the initiation and adjustment of therapy : a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2006, 29, 1963-1972.
Kahn SE, Haffner SM, Heise MA, et al for the ADOPT Study Group. - Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med, 2006, 355, 2427-2443.
Richter B, Bandeira-Echtler E, Bergerhoff K, et al. - Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev, 2007 (3): CD006063.
Chiquette E, Ramirez G, DeFronzo R. - A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med, 2004, 164, 2097-3104.
Scheen AJ, Van Gaal LF. - Le diabète de type 2 au coeur du syndrome métabolique : plaidoyer pour une prise en charge globale. Rev Med Liège, 2005, 60, 566-571.
Riche DM, Valderrama R, Henyan NN. - Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a metaanalysis. Diabetes Care, 2007, 30, 384-388.
Rosmarakis ES, Falagas ME. - Effect of thiazolidinedione therapy on restenosis after coronary stent implantation: a meta-analysis of randomized controlled trials. Am Heart J, 2007, 154, 144-150.
Scheen AJ, Lefèbvre PJ. - L'étude PROactive : prévention secondaire des accidents cardio-vasculaires par la pioglitazone chez le patient diabétique de type 2. Rev Med Liège, 2005, 60, 896-901.
Dormandy J, Charbonnel B, Eckland DJA, et al. - Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events) : a randomised controlled trial. Lancet, 2005, 366, 1279-1289.
Yki-Järvinen H. - The PROactive study : some answers, many questions. Lancet, 2005, 366, 1241-1242.
Erdmann E, Dormandy JA, Charbonnel B, et al, on behalf of the PROactive Investigators. - The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. J Am Coll Cardiol, 2007, 49, 1772-1780.
Nesto RW, Bell D, Bonow RO, et al. - Thiazolidinedione use, fluid retention, and congestive heart failure. A consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care, 2004, 27, 256-263.
De Flines J, Scheen AJ.- Glitazones et insuffisance cardiaque : les point sur les études PROactive, ADOPT, DREAM et RECORD. Rev Med Suisse. 2007, 3, 1876-1883.
Nissen SE, Wolski K. - Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med, 2007, 356, 2457-2471.
Home PD, Pocock SJ, Beck-Nielsen H, et al. - Rosiglitazone Evaluated for Cardiovascular Outcomes - An interim analysis. N Engl J Med, 2007, 357, 28-38.
Rosen CJ. - The rosiglitzone story - lessons from an FDA Advisory Committee Meeting. N Engl J Med, 2007, 357, 844-846.
Krall RL. - Cardiovascular safety of rosiglitazone. Lancet, 2007, 369, 1995-1996.
Kazi D. - Rosiglitazone and implications for pharmacovigilance. BMJ, 2007, 334, 1233-1234.
Fuster V, Farkouh ME. - Faster publication isn't always better. Nature Clin Pract, 2007, 4, 345.
Diamond GA, Bax L, Kaul S. - Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. 2007. 8. August 6 (Epub ahead of print).
Scheen AJ. - Comment j'explore... les secrets d'une méta-analyse. Rev Med Liège. 2003, 58, 41-46.
Psaty BM, Furberg CD. - Rosiglitazone and cardiovascular risk. N Engl J Med, 2007, 356, 2522-2524.
Home PD, Pocock SJ, Beck-Nielsen H, et al. - Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) : study design and protocol. Diabetologia, 2005, 48, 1726-1735.
Scheen AJ. - Comment j'explore ... les critères de jugement dans les essais cliniques : réflexion à propos d'études récentes de prévention cardio-vasculaire. Rev Med Liège. 2006, 61, 260-266.
Nathan DM. - Rosiglitazone and cardiotoxicity - Weighing the evidence. N Engl J Med, 2007, 357, 64-66.
Psaty BM, Furberg CD. - The Record on rosiglitazone and the risk of myocardial infarction. N Engl J Med, 2007, 357, 67-69.
Drazen JM, Morrissey S, Curfman GD. - Rosiglitazone - Continued uncertainty about safety. N Engl J Med. 2007, 357, 63-64.
Johannes CB, Koro CE, Quinn SG, et al. - The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf, 2007, 16, 504-512.
McAfee AT, Koro C, Landon J, et al. - Coronary heart disease outcomes in patients receiving antidiabetic agents Pharmacoepidemiol Drug Saf 2007, 16, 711-725.
FDA Advisory Committee : http://www.fda.gov/ohrms/dockets/ac/cder07. htm#EndocrinologicMetabolic
Scheen A.J. - Combined thiazolidinedione-insulin therapy. Should we be concerned about safetv? Drug Safety. 2004, 27, 841-856.